TABLE 5.
Change over time |
|||
Treatment | Baseline to 6 wk | 6 wk to 12 wk | Baseline to 12 wk |
Whole-body LM, g | |||
PB | 1930 (1129, 2750) | 945 (132, 1760) | 2880 (2060, 3690) |
WP | 1670 (819, 2520) | 623 (−265, 1510) | 2290 (1410, 3180) |
MDP | 1720 (874, 2580) | 318 (−570, 1210) | 2040 (1160, 2930) |
Arm LM, g | |||
PB | 393 (249, 538) | 180 (38, 330) | 576 (431, 720) |
WP | 321 (170, 473) | 130 (−32, 280) | 447 (290, 605) |
MDP | 341 (190, 493) | 65 (−93, 220) | 406 (249, 564) |
Leg LM, g | |||
PB | 1000 (600, 1400) | 94 (−310, 500) | 1100 (694, 1500) |
WP | 772 (352, 1190) | 93 (−350, 530) | 865 (428, 1300) |
MDP | 770 (350, 1190) | 78 (−360, 520) | 849 (411, 1290) |
Appendicular LM, g | |||
PB | 1390 (943, 1840) | 219 (−172, 730) | 1670 (1220, 2120) |
WP | 1090 (618, 1560) | 219 (−273, 711) | 1310 (817, 1800) |
MDP | 1120 (642, 1590) | 142 (−351, 634) | 1260 (764, 1750) |
Trunk LM, g | |||
PB | 475 (−147, 1100) | 806 (172, 1440) | 1280 (647, 1910) |
WP | 634 (−17, 1290) | 352 (−327, 1030) | 986 (308, 1660) |
MDP | 491 (−161, 1140) | 252 (−442, 946) | 742 (49, 1440) |
Values are means (95% CIs). Sample sizes/group at baseline, 6 wk, and 12 wk, respectively—MDP: n = 23, 20, and 18; PB: n = 23, 22, and 22; and WP: n = 22, 20, and 18. LM, lean mass; MDP, maltodextrin placebo; PB, soy-dairy protein blend; WP, whey protein.